Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia Authors: Danielle M Brander, Andrew W Roberts, Thomas J Kipps, Shuo Ma, Mary Ann Anderson, Michelle Boyer, Piers Blombery, Relja Popovic, Jordan Roser, Zhuangzhuang Liu, Brenda Chyla, John F Seymour Published: 2025 Treatment approaches for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have evolved significantly in recent years with the incorporation of novel therapies including those targeting Bruton tyrosine kinase (BTK) downstream of B‐cell receptor signaling as well as venetoclax, a potent inhibitor of the antiapoptotic B‐cell lymphoma 2 (BCL2) protein. 1 , 2 However, despite these therapeutic advances improving outcomes versus chemoimmunotherapy, 3 , 4 CLL remains incurable for most patients. Time‐limited approaches with these targeted agents are attractive due to the potential for fewer adverse events, reduced patient burden, lower costs, and, theoretically, a reduced risk of selection for resistance mutations. 5 , 6 As most patients with CLL/SLL will suffer disease relapse after their first treatment, the need remains for understanding effective strategies in the relapsed/refractory (R/R) setting, including options for retreatment that have the potential to extend the duration of benefit of a drug class used previously. Venetoclax is approved in combination with obinutuzumab for treatment‐naive CLL, and venetoclax is approved in R/R CLL as monotherapy or in combination with rituximab; treatment with venetoclax plus rituximab (VenR) for up to 2 years has demonstrated durable remissions in patients with R/R CLL/SLL that can be sustained off treatment. 1 , 2 In addition to limited cost and toxicities, fixed‐duration regimens are of interest given their potential to avoid the resistance that could compromise the effectiveness of later lines of treatment independent of the drug target. Patients with double BTK inhibitor (BTKi)/BCL2 inhibitor (BCL2i) exposures have no standardized approach to their disease management; survival in this group of patients is discouragingly short, and the subsequent duration of response to recently approved noncovalent BTKi is also shortened in this group of patients. 7 , 8 , 9 It remains an area of interest to understand strategies to extend disease control with the available agents. The M13‐365, a Phase 1b study examining the safety and outcomes of patients treated with VenR, 10 was the first prospective trial demonstrating that patients with CLL in deep response (complete response [CR] or undetectable minimal residual disease [uMRD]) could stop therapy with venetoclax and achieve similar outcomes to those with continuous therapy. An analysis of 5‐year outcomes of patients with R/R CLL/SLL treated with VenR with fixed‐duration or continuous venetoclax in this study revealed that 74% of patients who achieved a deep response maintained their response for 5 years or longer. 10 Retreatment with venetoclax is of increasing importance given the recurrent nature of CLL/SLL, and there is great interest in understanding that this option may extend the duration of clinical benefit of VenR beyond the time of first progressive disease (PD). The aim of this long‐term follow‐up is to report the outcomes of patients (n = 9) treated on the M13‐365 clinical trial who attained a deep response (CR or uMRD) and elected per protocol amendment to discontinue venetoclax treatment and, on PD, reinitiated therapy with VenR. The Phase 1b study of VenR, M13‐365 (NCT01682616), was an open‐label, dose escalation and expansion cohort trial enrolling patients between August 6, 2012, and May 28, 2014 (Figure S1). Full eligibility has been previously described 10 , 11 ; patients with R/R CLL/SLL were eligible if they had an Eastern Cooperative Oncology Group performance status ≤ 1. The study was approved by the institutional review board at each participating site and was conducted according to the Declaration of Helsinki and the International Council on Harmonization Good Clinical Practice guidelines. All patients provided written informed consent. All patients had efficacy response assessments per 2008 International Workshop on CLL (iwCLL) criteria that included the use of computed tomography (CT) scans at the end of VenR combination treatment. MRD was assessed by 4–8 color flow cytometry in local laboratories, and uMRD was defined by <1 CLL cell present in 1 × 104/μL white blood cells. 10 Patients treated with VenR who achieved CR/CR with incomplete marrow recovery (CRi) or partial response (PR) with uMRD were permitted but not required per protocol amendment to stop venetoclax. Subsequently, patients who developed PD (iwCLL criteria or MRD progression defined as 2 consecutive peripheral blood [PB] MRD values > 10−4 or a single assessment > 10−3) could reinitiate VenR on protocol. Before retreatment, disease status was assessed by CT scan or magnetic resonance imaging and marrow biopsy. Venetoclax 400 mg was given orally daily after a 5‐week dose ramp‐up. Rituximab was given intravenously as early as Day 1 of Week 6 at 375 mg/m2, followed by 5 monthly doses at 500 mg/m2. Second responses were evaluated per the 2008 iwCLL criteria. 12 MRD assessments beyond the protocol follow‐up period were conducted per local institutional policy. Assessment of BCL2 mutations before or soon after retreatment using targeted next‐generation sequencing was available for six of the nine patients reinitiating treatment. 13 , 14 Forty‐nine patients were treated in M13‐365, of whom 33 achieved a deep response (CR/CRi or uMRD), with 16 electing to stop venetoclax after a median of 1.4 years on therapy. Of these, nine were retreated with VenR after disease progression off therapy and were assessed in this analysis (Table 1). Median age was 66 years (range, 58–79), and median number of prior therapies before their first VenR treatment was 2 (range, 1–4). Five patients (55%) had CLL with unmutated IGHV, and 2 with unknown status, and 2 patients (11%) had CLL with either del(17p) or mutated TP53. In response to initial therapy, six of nine patients achieved CR, and seven achieved PB and/or marrow uMRD (Table 1). Table 1Baseline demographics and treatment response.Prior to retreatmentGenomic featuresa, b Prior to initial treatmentBest responseBest MRD (10−4) StatusReason for discontinuationPtAge, yearsGenderNo. prior therapiesTime on initial therapy, daysTime on retreatment, daysLymphocyte count, ×109/LMaximum LN size, mmDel(17p) TP53 mutation IGHV unmutatedWith initial therapyWith retreatmentPrior to initial therapyPrior to retreatmentWith retreatmentA66M126697432.171NoNoYesCRCRuMRD BMuMRD PB and BMStudy closeB72F4280203713.721NoNoYesCRiCRMRD + PB and BMuMRD PB MRD + BMProgressive diseaseC71M2994105321.364NoNoUnknownCRPRuMRD PB and BMMRD + PB and BMProgressive diseaseD64F1139113020.622NoNoYesCRPRuMRD PB and BMMRD + PB and BMProgressive diseaseE66F229096551.646NoUnknownYesPRPRuMRD PB and BMMRD + PB and BMProgressive diseasec F79F320357417.727NoYesUnknownCRPRMRD + BMMRD + PB and BMProgressive diseaseG68M3121034029.322YesNoNoCRCRuMRD PB and BMMRD + PBWorsening orthostatic hypotensionH63M110356818.322NoNoYesCRiPRuMRD PB and BMMRD + PBPer patient request at 2 yearsI58F32431307.818NoNoNoCRPRuMRD PB and BMMRD + PBRisk of COVID Note: Data cutoff date: December 31, 2023. Patients B and G were missing. All were negative for del (17p); one patient (Patient E) had TP53 mutations with two variants detected.Abbreviations: BM, bone marrow; CR, complete response; CRi, CR with incomplete recovery; LN, lymph node; MRD, minimal residual disease; PB, peripheral blood; PR, partial response; Pt, patient; uMRD, undetectable MRD. a Six of the nine patients were tested for BCL2 mutation status (four before reinitiation; two after reinitiation), all of which were negative. b Seven of the nine patients were tested for del17p and/or TP53 mutations following initial VenR treatment and before retreatment. c Patient E had clinical progression in November 2024, which is after the data cutoff date (December 31, 2023). Baseline demographics and treatment response. Note: Data cutoff date: December 31, 2023. Patients B and G were missing. All were negative for del (17p); one patient (Patient E) had TP53 mutations with two variants detected. Abbreviations: BM, bone marrow; CR, complete response; CRi, CR with incomplete recovery; LN, lymph node; MRD, minimal residual disease; PB, peripheral blood; PR, partial response; Pt, patient; uMRD, undetectable MRD. Six of the nine patients were tested for BCL2 mutation status (four before reinitiation; two after reinitiation), all of which were negative. Seven of the nine patients were tested for del17p and/or TP53 mutations following initial VenR treatment and before retreatment. Patient E had clinical progression in November 2024, which is after the data cutoff date (December 31, 2023). These patients were off initial treatment for a median of 38.4 months (range, 17.3–68.7) before PD occurred (Figure 1). Median time from PD to VenR retreatment was 4.9 months (range, 0.5–35.5). As of December 31, 2023, all nine patients achieved a response of PR or better to retreatment with VenR (Figure 1). Four did not progress and have been off therapy for >1 year. Median progression‐free survival (PFS) following retreatment was 4.9 years (95% CI, 1.6–not evaluable [NE]) (58.7 months [95% CI, 18.7–NE]) (Figure S2). Measured from the start of their initial VenR treatment, median second progression‑free survival (PFS2) was 9.5 years (95% CI, 4.2–NE) (114.5 months [95% CI, 50.9–NE]) (Figure S2). The median overall survival is shown in Figure S3A (from initial treatment) and Figure S3B (from retreatment). Swimmer plot of clinical outcomes and duration of treatment. Data cutoff date: December 31, 2023. PD, progressive disease. aPatient E had clinical progression in November 2024, which is after the data cutoff date. Among the six patients analyzed for acquired mutations in BCL2 after venetoclax‐based therapies, none were detected in the four patients tested before reinitiation of VenR, or the remaining two that were tested after VenR reinitiation when significant disease burden remained present. Of the seven patients who were tested for del (17p) and/or TP53 mutations before retreatment, all were negative for the del (17p), and one patient was positive for a TP53 mutation. The M13‐365 study provided the first prospective evidence that CLL/SLL response can be maintained off treatment if patients achieved a deep response to initial VenR. Additionally, as the protocol had the distinctive option, but not requirement, to discontinue treatment if in a deep response, it permitted the within‐trial comparison that demonstrated that PFS off therapy in deep response was like that of patients who remained on continuous therapy after achieving deep response. 10 , 11 This long‐term follow‐up of the nine patients retreated with VenR for PD off therapy demonstrates that retreatment was safe and effective, achieving responses in 100% of patients. This approach resulted in a median PFS2 of 9.5 years from initial VenR treatment and 4.9 years from retreatment. Moreover, of the six patients tested for BCL2 mutations, none had a detectable BCL2 mutation, supporting the notion that use of fixed‐duration therapy, in addition to mitigating toxicity risk and cost, may reduce the risk of developing resistance to subsequent lines of therapy. 13 , 14 The median time off‐treatment before initiation of retreatment was longer in this cohort compared to other previous publications, 15 , 16 suggesting a potential correlation between time off‐treatment and identification of more favorable patient groups of efficacy for retreatment. Ongoing prospective trials such as ReVenG (NCT04895436) 17 are formally studying the feasibility and effectiveness of retreatment with venetoclax and obinutuzumab for patients who previously received venetoclax plus an anti‐CD20 antibody with/without X, where X is any other drug. These reported findings support venetoclax‐based retreatment as an option for patients with R/R CLL who progress after venetoclax‐based therapy. AUTHOR CONTRIBUTIONS Danielle M. Brander: Investigation; data curation; formal analysis; writing—review and editing. Andrew W. Roberts: Investigation; data curation; formal analysis; writing—review and editing. Thomas J. Kipps: Investigation; data curation; formal analysis; writing—review and editing. Shuo Ma: Investigation; data curation; formal analysis; writing—review and editing. Mary Ann Anderson: Investigation; writing—review and editing. Michelle Boyer: Investigation; writing—review and editing. Piers Blombery: Investigation; writing—review and editing. Relja Popovic: Investigation; formal analysis; writing—review and editing. Jordan Roser: Conceptualization; data curation; formal analysis; writing—review and editing; investigation. Zhuangzhuang Liu: Investigation; data curation; formal analysis; writing—review and editing. Brenda Chyla: Investigation; data curation; formal analysis; writing—review and editing. John F. Seymour: Conceptualization; investigation; data curation; formal analysis; writing—review and editing. CONFLICT OF INTEREST STATEMENT Danielle M. Brander: Grants paid to institution/site PI clinical trials: AbbVie, ArQule/Merck, AstraZeneca/Acerta (end 1/2023), BeiGene, BMS (former Juno/Celgene), Carna Biosciences, Catapult, DTRM (end 4/2023), Genentech, NeWave, Nurix, Pharmacyclics, and TG Therapeutics (end 4/2023). Consulting/advisory: AbbVie, Pharmacyclics, BeiGene, BMS, and Nurix. Andrew W. Roberts: Research funding from AbbVie and Johnson and Johnson; patent related to venetoclax use; recipient of a share in royalty payments related to venetoclax received by employer, the Walter and Eliza Hall Institute of Medical Research. Thomas J. Kipps: Consultancy/advisory role with AbbVie; research funding from AbbVie. Shuo Ma: Consultancy/advisory role for AbbVie, AstraZeneca, BeiGene, BMS, and Janssen; speakers bureau participation for AstraZeneca, BeiGene, and Lilly; research funding from AbbVie, AstraZeneca, BeiGene, Juno, and Loxo. Shuo Ma: Consultancy/advisory role for AbbVie, AstraZeneca, BeiGene, BMS, Invyvid, and Janssen; speakers bureau participation for AstraZeneca, BeiGene, and Lilly; research funding from AbbVie, AstraZeneca, BeiGene, Carna, Juno, Loxo, and Nurix. Mary Ann Anderson: Research funding from AbbVie; recipient of a share in royalty payments related to venetoclax received by their employer, the Walter and Eliza Hall Institute of Medical Research. Michelle Boyer: Employment with Roche and may hold stock or other options. Relja Popovic, Jordan Roser, Zhuangzhuang Liu, and Brenda Chyla: Employment with AbbVie and may hold stock or other options. John Francis Seymour: Consultancy/advisory role for and honoraria from AbbVie, Acerta, Celgene, Genentech, Janssen, Roche, Sunesis, and Takeda; speakers bureau participation for AbbVie, Celgene, and Roche; research funding, travel accommodations, and expenses from AbbVie, Janssen, Celgene, and Roche; expert testimony provided for Roche. FUNDING Venetoclax is being developed in collaboration between AbbVie and Genentech/Roche. AbbVie and Genentech/Roche funded this study and participated in the design, study conduct, analysis, interpretation of data, as well as the writing, review, and approval of the publication. No honoraria or payments were made for authorship. Editorial support was provided by BioConnections LLC, funded by AbbVie. AWR and MAA have received Investigator Grant support from the National Health and Medical Research Council of Australia (1174902, 2025453, and 2034294). Supporting information Supporting Information. ACKNOWLEDGMENTS AbbVie and the authors thank all the trial investigators and the patients who participated in this clinical trial. Medical writing support was provided by Marianne Pons, PhD, and Phillip Giannopoulos, PhD, CMPP, of Bio Connections, LLC. DATA AVAILABILITY STATEMENT AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial‐level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent, scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time after approval in the United States and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link: https://vivli.org/ourmember/abbvie/. Then, select “Home.” REFERENCES Associated Data Supplementary Materials Supporting Information. Data Availability Statement AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial‐level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent, scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time after approval in the United States and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link: https://vivli.org/ourmember/abbvie/. Then, select “Home.”